Table 1.
Demographic and clinical characteristics at baseline for human immunodeficiency virus (HIV) seropositive and seronegative women reporting sex with women (WSW) and a matched subset of women reporting sex with men (WSM). N (%)
| Characteristic | HIV+ | HIV− | P-value1 | ||
|---|---|---|---|---|---|
| WSW (N = 49) | WSM (N = 245) | WSW (N = 24) | WSM (N = 120) | ||
| Recruits2 | 1.00 | ||||
| 1994/95 | 42 (85.7) | 210 (85.7) | 16 (66.7) | 80 (66.7) | |
| 2001/02 | 7 (14.3) | 35 (14.3) | 8 (33.3) | 40 (33.3) | |
| Age group2 | 1.00 | ||||
| <30 | 3 (6.1) | 15 (6.1) | 3 (12.5) | 15 (12.5) | |
| 30–34 | 11 (22.5) | 55 (22.5) | 9 (37.5) | 45 (37.5) | |
| 35–39 | 19 (38.8) | 95 (38.8) | 5 (20.8) | 25 (20.8) | |
| 40–44 | 7 (14.3) | 35 (14.3) | 5 (20.8) | 25 (20.8) | |
| >=45 | 9 (18.4) | 45 (18.4) | 2 (8.3) | 10 (8.3) | |
| Race/Ethnicity | 0.07 | ||||
| White | 13 (26.5) | 38 (15.5) | 6 (25.0) | 14 (11.7) | |
| Hispanic | 9 (18.4) | 67 (27.4) | 9 (37.5) | 33 (27.5) | |
| Black | 26 (53.1) | 131 (53.5) | 9 (37.5) | 66 (55.0) | |
| Others | 1 (2.0) | 9 (3.7) | 0 (0) | 7 (5.8) | |
| Smoking | 0.02 | ||||
| Never smoked | 8 (16.3) | 79 (32.4) | 5 (20.8) | 37 (31.1) | |
| Former smoker | 11 (22.5) | 40 (16.4) | 1 (4.2) | 16 (13.5) | |
| Current smoker | 30 (61.2) | 125 (51.2) | 18 (75.0) | 66 (55.5) | |
| Sex with female in past 6 months | 0.173 | ||||
| No | 13 (26.5) | 245 (100.0) | 3 (12.5) | 120 (100.0) | |
| Yes | 36 (73.5) | 0 (0) | 21 (87.5) | 0 (0) | |
| CD4 Count2 (cells/cmm) | 1.003 | ||||
| >500 | 15 (31.3) | 75 (31.3) | |||
| 200–500 | 18 (37.5) | 90 (37.5) | |||
| <200 | 15 (31.3) | 75 (31.3) | |||
| HIV DNA level | 0.073 | ||||
| <=4000 | 21 (44.7) | 76 (31.5) | |||
| 4001–20,000 | 4 (8.5) | 52 (21.6) | |||
| 20,001–100,000 | 13 (27.7) | 50 (20.8) | |||
| >100,000 | 9 (19.2) | 63 (26.1) | |||
| HAART4 use past 6 months | 1.003 | ||||
| No | 45 (91.8) | 225 (91.8) | |||
| Yes | 4 (8.2) | 20 (8.2) | |||
1
Stratified test p-value for comparing WSWs and WSMs.
2
Matched variables.
3
Comparison is within WSWs.
4
Highly active antiretroviral therapy